Gilead Sciences Inc. [NASDAQ: GILD] loss -0.09% or -0.06 points to close at $68.09 with a heavy trading volume of 6383250 shares. The company report on June 15, 2021 that Jounce Therapeutics Achieves First Milestone in Exclusive License Agreement with Gilead Sciences and FDA Clearance of Investigational New Drug Application for Anti-CCR8 Antibody.
Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, announced the U.S. Food and Drug Administration’s (FDA) clearance of its Investigational New Drug (IND) application for JTX-1811, an anti-CCR8 antibody, for which Gilead Sciences, Inc. (Nasdaq: GILD) has exclusive rights to develop and commercialize. The IND clearance triggers a $25.0 million milestone payment to Jounce.
JTX-1811, which will be referred to as GS-1811 in Gilead’s pipeline, is a monoclonal antibody created by Jounce and designed to selectively deplete immunosuppressive tumor-infiltrating T regulatory (TITR) cells. The target of JTX-1811 is CCR8, a chemokine receptor enriched on TITR cells. When JTX-1811 binds to CCR8, it targets TITR cells for depletion by enhancing an antibody-dependent cellular cytotoxicity mechanism.
It opened the trading session at $68.48, the shares rose to $68.50 and dropped to $67.74, the range by which the price of stock traded the whole day. The daily chart for GILD points out that the company has recorded 12.06% gains over the past six months. However, it is still -20.39% lower than its most recent low trading price.
If we look at the average trading volume of 7.21M shares, GILD reached to a volume of 6383250 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Gilead Sciences Inc. [GILD]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for GILD shares is $74.49 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on GILD stock is a recommendation set at 2.40. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Bernstein have made an estimate for Gilead Sciences Inc. shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on April 01, 2021. The new note on the price target was released on March 30, 2021, representing the official price target for Gilead Sciences Inc. stock. Previously, the target price had yet another raise to $83, while Morgan Stanley analysts kept a Overweight rating on GILD stock.
The Average True Range (ATR) for Gilead Sciences Inc. is set at 1.15, with the Price to Sales ratio for GILD stock in the period of the last 12 months amounting to 3.37. The Price to Book ratio for the last quarter was 4.51, with the Price to Cash per share for the same quarter was set at 4.48. Price to Free Cash Flow for GILD in the course of the last twelve months was 16.53 with Quick ratio for the last quarter at 1.20.
Trading performance analysis for GILD stock
Gilead Sciences Inc. [GILD] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 0.86. With this latest performance, GILD shares dropped by -0.64% in over the last four-week period, additionally plugging by 12.06% over the last 6 months – not to mention a drop of -7.95% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for GILD stock in for the last two-week period is set at 55.08, with the RSI for the last a single of trading hit 55.08, and the three-weeks RSI is set at 54.88 for Gilead Sciences Inc. [GILD]. The present Moving Average for the last 50 days of trading for this stock 66.64, while it was recorded at 68.59 for the last single week of trading, and 63.73 for the last 200 days.
Gilead Sciences Inc. [GILD]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and Gilead Sciences Inc. [GILD] shares currently have an operating margin of +42.38 and a Gross Margin at +81.70. Gilead Sciences Inc.’s Net Margin is presently recorded at +0.50.
Return on Total Capital for GILD is now 21.25, given the latest momentum, and Return on Invested Capital for the company is 0.27. Return on Equity for this stock inclined to 0.60, with Return on Assets sitting at 0.19. When it comes to the capital structure of this company, Gilead Sciences Inc. [GILD] has a Total Debt to Total Equity ratio set at 176.45. Additionally, GILD Total Debt to Total Capital is recorded at 63.83, with Total Debt to Total Assets ending up at 46.95. Long-Term Debt to Equity for the company is recorded at 160.71, with the Long-Term Debt to Total Capital now at 58.14.
Reflecting on the efficiency of the workforce at the company, Gilead Sciences Inc. [GILD] managed to generate an average of $9,044 per employee. Receivables Turnover for the company is 5.81 with a Total Asset Turnover recorded at a value of 0.38.Gilead Sciences Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.20 and a Current Ratio set at 1.40.
Gilead Sciences Inc. [GILD]: An earnings per share (EPS) analysis
With the latest financial reports released by the company, Gilead Sciences Inc. posted 1.11/share EPS, while the average EPS was predicted by analysts to be reported at 1.45/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -23.40%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for GILD. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Gilead Sciences Inc. go to 2.98%.
An analysis of insider ownership at Gilead Sciences Inc. [GILD]
There are presently around $66,842 million, or 80.40% of GILD stock, in the hands of institutional investors. The top three institutional holders of GILD stocks are: BLACKROCK INC. with ownership of 124,723,133, which is approximately 12.178% of the company’s market cap and around 0.09% of the total institutional ownership; CAPITAL RESEARCH GLOBAL INVESTORS, holding 122,606,338 shares of the stock with an approximate value of $8.35 billion in GILD stocks shares; and VANGUARD GROUP INC, currently with $7.1 billion in GILD stock with ownership of nearly 1.437% of the company’s market capitalization.
Positions in Gilead Sciences Inc. stocks held by institutional investors increased at the end of April and at the time of the April reporting period, where 787 institutional holders increased their position in Gilead Sciences Inc. [NASDAQ:GILD] by around 66,915,036 shares. Additionally, 741 investors decreased positions by around 56,762,176 shares, while 177 investors held positions by with 857,998,964 shares. The mentioned changes placed institutional holdings at 981,676,176 shares, according to the latest SEC report filing. GILD stock had 151 new institutional investments in for a total of 10,453,642 shares, while 132 institutional investors sold positions of 8,592,821 shares during the same period.